SCHEMBL5338353

SCHEMBL5338353

Nc1cccc(CN2CCCC(O)C2)n1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.55
TSHR P16473 1/20 0.54
KDM4E B2RXH2 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
POLB P06746 2/20 0.51
HPGD P15428 1/20 0.51
HTT P42858 2/20 0.51
PDE8B O95263 1/20 0.43
KMT2A Q03164 2/20 0.42
MAPT P10636 1/20 0.42
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAP4K4 O95819 2/20 0.41
APP P05067 1/20 0.40
BACE1 P56817 1/20 0.40
LTA4H P09960 1/20 0.40
JAK2 O60674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23425814 0.92 TSHR (0.44) ALDH1A1TSHRKDM4ESMN1; SMN2POLB
SCHEMBL5345901 0.83 ALDH1A1 (0.55) ALDH1A1TSHRKDM4ESMN1; SMN2POLB
SCHEMBL5337678 0.83 LMNA (0.60) ALDH1A1KDM4ESMN1; SMN2HPGDPDE8B
SCHEMBL5343494 0.82 CXCR4 (0.46) MAPTL3MBTL1APPBACE1
SCHEMBL5344817 0.82 GAA (0.56) ALDH1A1KDM4ESMN1; SMN2PDE8BKMT2A
SCHEMBL5347719 0.82 ALDH1A1 (0.54) ALDH1A1TSHRKDM4ESMN1; SMN2PDE8B
SCHEMBL465821 0.80 CXCR4 (0.53) ALDH1A1KDM4EHPGDL3MBTL1APP
SCHEMBL29501398 0.80 ALDH1A1 (0.58) ALDH1A1TSHRKDM4ESMN1; SMN2POLB
SCHEMBL5342190 0.79 CXCR4 (0.51) ALDH1A1KDM4ESMN1; SMN2POLBHPGD
Hydrochloric Acid SCHEMBL2149315 0.79 CXCR4 (0.51) ALDH1A1KDM4EHPGDAPPBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196104-B2 Thiazolyl urea compounds and methods of uses AMGEN, INC. (US) 2007-03-27 US disclosed
EP-1309589-B1 UREA COMPOUNDS AND METHODS OF USES AMGEN INC (US) 2006-03-15 EP disclosed
EP-1619184-A2 Urea compounds as kinase inhibitors Amgen, Inc. (US) 2006-01-25 EP disclosed
EP-1483263-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2004-12-08 EP disclosed
US-20040039029-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2004-02-26 US disclosed
US-6645990-B2 For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases AMGEN INC. 2003-11-11 US disclosed
WO-2003070727-A1 THIAZOLYL UREA COMPOUNDS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2003-08-28 WO disclosed
US-20020193405-A1 Thiazolyl urea compounds and methods of uses AMGEN INC. 2002-12-19 US disclosed
US-20020173507-A1 Urea compounds and methods of uses AMGEN INC. 2002-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193405-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX ALDH1A1 810/4885TSHR 2356/4885KDM4E 2714/4885
US-20020173507-A1 Urea compounds and methods of uses SLC14A1, UMPS, BAX ALDH1A1 865/4885TSHR 4460/4885KDM4E 1709/4885
US-20040039029-A1 Thiazolyl urea compounds and methods of uses SLC14A1, UMPS, BAX ALDH1A1 810/4885TSHR 2356/4885KDM4E 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.